Sugi Predict

Sugi Predict / Compounds / SCHEMBL165740

SCHEMBL165740

SCHEMBL165740

CCOc1ccc(Br)nc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NQO1 P15559 1/20 0.54
▸ CHRNB2 P17787 2/20 0.47
▸ CHRNA4 P43681 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ LTA4H P09960 2/20 0.42
▸ MAPT P10636 4/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.38
▸ RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31038327 1.00 NQO1 (0.54) NQO1CHRNB2CHRNA4TDP1TSHR
SCHEMBL31408221 0.84 CHRNB2 (0.43) NQO1CHRNB2CHRNA4TDP1TSHR
SCHEMBL1109106 0.83 CYP2D6 (0.47) CHRNB2CHRNA4LTA4HMAPTRAB9A
SCHEMBL256095 0.83 CHRNB2 (0.45) CHRNB2CHRNA4LTA4HMAPTRAB9A
SCHEMBL20539460 0.80 CHRNB2 (0.40) CHRNB2CHRNA4
SCHEMBL1025426 0.79 CHRNB2 (0.45) CHRNB2CHRNA4
SCHEMBL29349923 0.79 CHRNB2 (0.45) CHRNB2CHRNA4
SCHEMBL17825379 0.79 NR5A1 (0.53) TSHRLTA4HMAPTRAB9AKDM4E
Dimethylamine SCHEMBL28977151 0.79 PLK1 (0.44) CHRNB2CHRNA4LTA4HMAPTRAB9A
SCHEMBL15740704 0.79 NR5A1 (0.53) TSHRLTA4HMAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 — — CN disclosed
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC 2025-04-17 — — US disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 — — EP disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 — — WO disclosed
WO-2010100144-A1 FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE MERCK SERONO S.A. (CH) 2010-09-10 — — WO disclosed
CN-101410393-A Novel heteroaryl substituted benzothiazoles ASTRAZENECA AB (SE) 2009-04-15 — — CN disclosed
US-20090028787-A1 Novel Heteroaryl Substituted Benzothiazoles NAVIDEA BIOPHARMACEUTICALS, INC. 2009-01-29 — — US disclosed
EP-1981883-A1 NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES AstraZeneca AB (SE) 2008-10-22 — — EP disclosed
WO-2007086800-A1 NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 — — EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 — — US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 — — US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 NQO1 3862/4885CHRNB2 4631/4885CHRNA4 4823/4885
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D NQO1 1973/4885CHRNB2 511/4885CHRNA4 54/4885
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L NQO1 4045/4885CHRNB2 4604/4885CHRNA4 4586/4885
US-20090028787-A1 Novel Heteroaryl Substituted Benzothiazoles APP, MAPT, PSEN1 NQO1 1553/4885CHRNB2 718/4885CHRNA4 1499/4885
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 NQO1 209/4885CHRNB2 4832/4885CHRNA4 4647/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 NQO1 3862/4885CHRNB2 4631/4885CHRNA4 4823/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 NQO1 2369/4885CHRNB2 2163/4885CHRNA4 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.